$ESPR News

Esperion Presents Data From Phase 2 Trial Of Bempedoic Acid In Children Along With Post Hoc Analysis From CLEAR Outcomes At European Atherosclerosis Society Congress 2026

Epilogue On Esperion Therapeutics (Rating Downgrade)

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026

Esperion Therapeutics To Present Two New Analyses On Various Applications Of Bempedoic Acid At The European Atherosclerosis Society (EAS) Congress 2026 May 24-27

Needham Downgrades Esperion Therapeutics to Hold

What's Going On With Esperion Therapeutics Stock On Monday?

HC Wainwright & Co. Downgrades Esperion Therapeutics to Neutral, Announces $3.16 Price Target

ARCHIMED to acquire Esperion Therapeutics in $1.1 billion deal

Esperion to be Acquired by ARCHIMED

Esperion Therapeutics To Be Acquired By ARCHIMED For $3.16 Per Share In Cash Plus Right To Milestone Payments Of Up To $100M

Esperion to Report First Quarter 2026 Financial Results on May 7

Esperion Therapeutics Highlights 38% Revenue Growth, Enbumyst Launch Plan at Needham Conference

Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics

Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

Athyrium Capital Management And Esperion Therapeutics Enter $50M Royalty Financing Agreement On Japanese Sales Of Bempedoic Acid Products

Athyrium Capital Management And Esperion Therapeutics Enter $50M Royalty Financing Agreement On Japanese Sales Of Bempedoic Acid Products

Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference

Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026

Esperion Announces Presentation Of Two Post-Hoc Analyses Of NEXLETOL As A Treatment For Cardiovascular Risk At American College of Cardiology's Annual Scientific Session (ACC.26) March 28-30